How is COVID-19 impacting oncology clinical trials?

A visualisation of suspended and resumed oncology clinical trials due to COVID-19.
01 June 2020
empty infusion bed
Greg Schuman
Greg
Schuman

Consultant II, Health Division

Pruthvi Shah
Pruthvi
Shah

Associate Consultant I, Health Division

Haris Vikis
Haris
Vikis

Senior Consultant, Health Division, US

Get in touch

The impact of COVID-19 on oncology clinical trials is clear.  Over 100 trials have been suspended over recent months and the impact to patients, in addition to slowed recruitment, is potentially immense. This interactive dashboard allows you to visualise details of both suspended and resumed clinical trials as a result of COVID-19 and gain insights including:

  • A high proportion of suspended trials are academic/government sponsored
  • Almost half of suspended trials are for immunotherapies, and many are for those explored as combinations with other agents
  • Approximately one-third of trials have resumed recruiting since their initial suspension

Click the image below to filter and identify trial sponsors, drug owners, tumor types, drugs that are impacted, and dive into further detail to view by drug technology, class and target.

Impact of COVID-19 on clinical trials

These data are a product of CancerLandscape™, a module of the CancerMPact®. Kantar will continue to update the COVID-19 Impact on Oncology viewer on a monthly basis. Note that while this underestimates the full impact of COVID-19, as updates to trial registries are voluntary, data from Medidata1 suggests ~50% year over year decrease in new patients entering oncology trials.

Contact us to learn more about the CancerLandscape and how it can help you understand the complete drug and trial landscape across US and EU trial registries.

1COVID 19 and Clinical Trials Release 5.0

 

Get in touch
Related solutions
Identify and screen oncology development targets with breakthrough potential quickly, comprehensively and accurately.
A cross-sectional study with retrospective elements conducted by Kantar every two years.
Specialised data and insights to commercialise oncology products, manage risks and improve patient outcomes.